sanofi-aventis has gained full control over Genzyme, bringing the much talked about acquisition deal between the two companies to a close. In a press statement, sanofi-aventis announced that approximately 84.6% of Genzyme's outstanding shares had been tendered for $74/ share in cash, giving the company ownership of approximately 77% of the shares on a fully diluted basis. The offer was made in February after Genzyme rejected the previous offer of $69/share.
The acquisition will give sanofi-aventis an expanded presence in the biotechnology field, sanofi-aventis and Genzyme …
Комментариев нет:
Отправить комментарий